Press Releases

Press Release: Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]


August 17, 2022
Reset
Atomwise Announces Growing Portfolio of Joint Venture Companies

Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informa’s Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. SAN FRANCISCO, Calif., December 21, 2020 – Atomwise, the leader in […]


December 21, 2020
Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December  18, 2020 – Atomwise, the leader in using artificial […]


December 18, 2020
Atomwise grant funding announcement from the Gates Foundation
Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis

The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network SAN FRANCISCO, CA — October 6th, 2020 — Atomwise, the leader in using artificial intelligence (AI) for small […]


October 6, 2020
Atomwise and GC Pharma partnership
GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

The partnership will develop new drug programs that advance GC Pharma’s global leadership in hemophilia and additional disease areas SAN FRANCISCO & YONGIN, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross […]


September 8, 2020
Atomwise Named to the 2020 CB Insights Digital Health 150 — List of Most Innovative Digital Health Startups

Atomwise recognized for achievements in AI-driven drug discovery and creation of the AtomNet® platform, which has tackled — and succeeded in — finding small molecule hits for more undruggable targets than any other platform NEW YORK, August 13, 2020 — CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases […]


August 13, 2020
Atomwise sign in office
Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil

New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery SAN FRANCISCO — August 11, 2020 — Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 […]


August 11, 2020
  1. Pages:
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7